
Reidar Fossmark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4964868/publications.pdf Version: 2024-02-01



REIDAD FOSSMADE

#	Article	IF	CITATIONS
1	Hypergastrinemia and mortality in gastric adenocarcinoma: a population-based cohort study, the HUNT study. Scandinavian Journal of Gastroenterology, 2022, , 1-8.	0.6	1
2	Safety and Efficacy of Local Tranexamic Acid for the Prevention of Surgical Bleeding in Soft-Tissue Surgery: A Review of the Literature and Recommendations for Plastic Surgery. Plastic and Reconstructive Surgery, 2022, 149, 774-787.	0.7	23
3	Do Gastric Signet Ring Cell Carcinomas and ECL-Cell Neuroendocrine Tumours Have a Common Origin?. Medicina (Lithuania), 2022, 58, 470.	0.8	3
4	Reply to "Too Soon to Dismiss Inflammation-Related Differences in the Mucosa-Associated Microbiota in Crohn's Disease Patientsâ€: Inflammatory Bowel Diseases, 2022, , .	0.9	0
5	Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: A prospective populationâ€based nested caseâ€control study. International Journal of Cancer, 2021, 148, 1879-1886.	2.3	9
6	Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110217.	1.4	0
7	Gastritis, Gastric Polyps and Gastric Cancer. International Journal of Molecular Sciences, 2021, 22, 6548.	1.8	59
8	Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?. Bone Reports, 2021, 14, 101095.	0.2	0
9	Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort. Cancers, 2021, 13, 3985.	1.7	5
10	Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2021, 27, 12-24.	0.9	46
11	Gastric Cancers Missed at Upper Endoscopy in Central Norway 2007 to 2016—A Population-Based Study. Cancers, 2021, 13, 5628.	1.7	13
12	Survival and disease recurrence in patients operated for small intestinal neuroendocrine tumors at a referral hospital. Surgical Oncology, 2020, 35, 336-343.	0.8	12
13	Gastric Corpus Mucosal Hyperplasia and Neuroendocrine Cell Hyperplasia, but not Spasmolytic Polypeptide-Expressing Metaplasia, Is Prevented by a Gastrin Receptor Antagonist in H+/K+ATPase Beta Subunit Knockout Mice. International Journal of Molecular Sciences, 2020, 21, 927.	1.8	1
14	Enterochromaffin-Like (ECL) Cells. , 2020, , 265-272.		0
15	Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection. Scandinavian Journal of Gastroenterology, 2019, 54, 1003-1007.	0.6	8
16	Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility. International Journal of Molecular Sciences, 2019, 20, 5203.	1.8	92
17	Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis—what can we learn? Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1532-1532.	1.9	0
18	Mucosal 5â€aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1301-1313.	1.9	30

#	Article	IF	CITATIONS
19	The Phylogeny and Biological Function of Gastric Juice—Microbiological Consequences of Removing Gastric Acid. International Journal of Molecular Sciences, 2019, 20, 6031.	1.8	45
20	Role of Autoimmune Gastritis in Gastric Cancer. Clinical and Translational Gastroenterology, 2019, 10, e00080.	1.3	9
21	Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells. Hormones and Cancer, 2018, 9, 40-54.	4.9	23
22	Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man. Gut, 2018, 67, 199.2-200.	6.1	21
23	Types of Gastric Carcinomas. International Journal of Molecular Sciences, 2018, 19, 4109.	1.8	78
24	Proton pump inhibitors (PPIs) may cause gastric cancer – clinical consequences. Scandinavian Journal of Gastroenterology, 2018, 53, 639-642.	0.6	33
25	Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481877505.	1.4	14
26	Netazepide, a gastrin/cholecystokininâ€⊋ receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. British Journal of Clinical Pharmacology, 2017, 83, 466-475.	1.1	49
27	The cytoprotective protein clusterin is overexpressed in hypergastrinemic rodent models of oxyntic preneoplasia and promotes gastric cancer cell survival. PLoS ONE, 2017, 12, e0184514.	1.1	9
28	Effects of the Histamine 1 Receptor Antagonist Cetirizine on the Osteoporotic Phenotype in H ⁺ /K ⁺ ATPase Beta Subunit KO Mice. Journal of Cellular Biochemistry, 2016, 117, 2089-2096.	1.2	7
29	ECLâ€cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H ⁺ K ⁺ ATPase alpha subunit. Apmis, 2016, 124, 561-566.	0.9	30
30	PAI-1 deficiency increases the trophic effects of hypergastrinemia in the gastric corpus mucosa. Peptides, 2016, 79, 83-94.	1.2	8
31	The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours. European Journal of Gastroenterology and Hepatology, 2016, 28, 1345-1352.	0.8	6
32	Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease. JAMA Internal Medicine, 2016, 176, 868.	2.6	2
33	Follow-up of patients with ECL cell-derived tumours. Scandinavian Journal of Gastroenterology, 2016, 51, 1398-1405.	0.6	8
34	Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice. Journal of Endocrinology, 2016, 230, 251-262.	1.2	9
35	Impaired skeletal health in patients with chronic atrophic gastritis. Scandinavian Journal of Gastroenterology, 2016, 51, 774-781.	0.6	20
36	Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?. Scandinavian Journal of Gastroenterology, 2016, 51, 767-773.	0.6	18

#	Article	IF	CITATIONS
37	Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival. Apmis, 2015, 123, 509-514.	0.9	32
38	Upper gastrointestinal physiology and diseases. Scandinavian Journal of Gastroenterology, 2015, 50, 649-656.	0.6	12
39	Fecal calprotectin in patients with suspected small bowel disease – a selection tool for small bowel capsule endoscopy?. Scandinavian Journal of Gastroenterology, 2015, 50, 272-277.	0.6	17
40	Letter: proton pump inhibitors, hypergastrinaemia and the risk of gastric neoplasia. Alimentary Pharmacology and Therapeutics, 2015, 42, 389-389.	1.9	2
41	Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach. Digestive Diseases and Sciences, 2015, 60, 1522-1527.	1.1	41
42	The gastric mucosa 25 years after proximal gastric vagotomy. Scandinavian Journal of Gastroenterology, 2014, 49, 1173-1180.	0.6	4
43	Cytomegalovirus infection and postoperative complications in patients with ulcerative colitis undergoing colectomy. Scandinavian Journal of Gastroenterology, 2014, 49, 845-852.	0.6	9
44	The regulation of gastric acid secretion – clinical perspectives. Acta Physiologica, 2014, 210, 239-256.	1.8	57
45	Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocrine-Related Cancer, 2014, 21, R445-R460.	1.6	44
46	The effects of unilateral truncal vagotomy on gastric carcinogenesis in hypergastrinemic Japanese female cotton rats. Regulatory Peptides, 2013, 184, 62-67.	1.9	3
47	Serotonin in blood: Assessment of its origin by concomitant determination of β-thromboglobulin (platelets) and chromogranin A (enterochromaffin cells). Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 148-153.	0.6	6
48	The Distressing Overuse of Gastric Acid Inhibitors. Digestive Diseases and Sciences, 2013, 58, 600-601.	1.1	2
49	Symptomatic Primary (AL) Amyloidosis of the Stomach and Duodenum. Case Reports in Gastrointestinal Medicine, 2013, 2013, 1-3.	0.2	9
50	Development of diffuse carcinomas in the gastric corpus in patients with rugal hyperplastic gastritis. International Journal of Cancer, 2013, 133, 2260-2260.	2.3	0
51	Immunohistochemical evidence for an impairment of autophagy in tumorigenesis of gastric carcinoids and adenocarcinomas in rodent models and patients. Histology and Histopathology, 2013, 28, 531-42.	0.5	16
52	Gastric Carcinomas Localized to the Cardia. Gastroenterology Research and Practice, 2012, 2012, 1-6.	0.7	2
53	Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scandinavian Journal of Gastroenterology, 2012, 47, 64-67.	0.6	70
54	Gastric carcinoids after longâ€ŧerm use of a proton pump inhibitor. Alimentary Pharmacology and Therapeutics, 2012, 36, 644-649.	1.9	104

#	Article	IF	CITATIONS
55	Regulated endocrine-specific protein 18 (RESP18) is localized to and regulated in A-like cells and G-cells in rat stomach. Regulatory Peptides, 2012, 177, 53-59.	1.9	4
56	Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scandinavian Journal of Gastroenterology, 2012, 47, 649-657.	0.6	16
57	Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Alimentary Pharmacology and Therapeutics, 2012, 36, 1067-1075.	1.9	94
58	Withdrawing PPI Therapy: Response to Metz et al American Journal of Gastroenterology, 2012, 107, 325-326.	0.2	1
59	Decreased bone mineral density and reduced bone quality in H ⁺ /K ⁺ ATPase betaâ€subunit deficient mice. Journal of Cellular Biochemistry, 2012, 113, 141-147.	1.2	21
60	The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocrine Disorders, 2011, 11, 11.	0.9	55
61	Skeletal Effects of the Saturated 3-Thia Fatty Acid Tetradecylthioacetic Acid in Rats. PPAR Research, 2011, 2011, 1-10.	1.1	3
62	Animal Models to Study the Role of Long-Term Hypergastrinemia in Gastric Carcinogenesis. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-6.	3.0	15
63	Parietal cell activation by arborization of ECL cell cytoplasmic projections is likely the mechanism for histamine induced secretion of hydrochloric acid. Scandinavian Journal of Gastroenterology, 2011, 46, 531-537.	0.6	17
64	Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scandinavian Journal of Gastroenterology, 2011, 46, 456-463.	0.6	50
65	Neuroendocrine Cells in Diffuse Gastric Carcinomas. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 62-68.	0.6	9
66	A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumor Biology, 2010, 31, 373-380.	0.8	23
67	Long-term gastric changes in achlorhydric H+/K+-ATPase beta subunit deficient mice. Scandinavian Journal of Gastroenterology, 2010, 45, 1042-1047.	0.6	11
68	Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scandinavian Journal of Gastroenterology, 2010, 45, 389-394.	0.6	61
69	Effect of antrectomy in hypergastrinaemic female Japanese cotton rats. Scandinavian Journal of Gastroenterology, 2009, 44, 32-39.	0.6	2
70	Interactions between gastric acid secretagogues and the localization of the gastrin receptor. Scandinavian Journal of Gastroenterology, 2009, 44, 390-393.	0.6	11
71	Gastric cancer: Animal studies on the risk of hypoacidity and hypergastrinemia. World Journal of Gastroenterology, 2008, 14, 1646.	1.4	27
72	Classification of tumours. Journal of Experimental and Clinical Cancer Research, 2008, 27, 70.	3.5	31

#	Article	IF	CITATIONS
73	Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scandinavian Journal of Gastroenterology, 2008, 43, 20-24.	0.6	51
74	Changes in gene expression of gastric mucosa during therapeutic acid inhibition. European Journal of Gastroenterology and Hepatology, 2008, 20, 613-623.	0.8	12
75	pH 4.0. Scandinavian Journal of Gastroenterology, 2007, 42, 297-298.	0.6	3
76	Rebound acid hypersecretion. Alimentary Pharmacology and Therapeutics, 2007, 25, 999-1000.	1.9	3
77	Signet Ring Cells in Gastric Carcinomas Are Derived from Neuroendocrine Cells. Journal of Histochemistry and Cytochemistry, 2006, 54, 615-621.	1.3	69
78	Molecular characterization of rat gastric mucosal response to potent acid inhibition. Physiological Genomics, 2005, 22, 24-32.	1.0	22
79	Idiopathic gastric acid hypersecretion. European Journal of Gastroenterology and Hepatology, 2005, 17, 1433.	0.8	0
80	Experimental Helicobacter pylori Infection Induces Antral-Predominant, Chronic Active Gastritis in Hispid Cotton Rats (Sigmodon hispidus). Helicobacter, 2005, 10, 332-344.	1.6	10
81	Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Alimentary Pharmacology and Therapeutics, 2005, 21, 149-154.	1.9	106
82	Dedifferentiation of enterochromaffin-like cells in gastric cancer of hypergastrinemic cotton rats. Apmis, 2005, 113, 436-449.	0.9	18
83	Ultrastructure and chromogranin A immunogold labelling of ECL cell carcinoids. Apmis, 2005, 113, 506-512.	0.9	17
84	Antiulcer Drugs and Gastric Cancer. Digestive Diseases and Sciences, 2005, 50, S39-S44.	1.1	38
85	Long-Term Serotonin Administration Induces Heart Valve Disease in Rats. Circulation, 2005, 111, 1517-1522.	1.6	229
86	ECL-Cell Derived Gastric Cancer in Male Cotton Rats Dosed with the H2-Blocker Loxtidine. Cancer Research, 2004, 64, 3687-3693.	0.4	29
87	Spontaneous enterochromaffin-like cell carcinomas in cotton rats (Sigmodon hispidus) are prevented by a somatostatin analogue Endocrine-Related Cancer, 2004, 11, 149-160.	1.6	11
88	Hypergastrinaemia induced by partial corpectomy results in development of enterochromaffinâ€like cell carcinoma in male Japanese cotton rats. Scandinavian Journal of Gastroenterology, 2004, 39, 919-926.	0.6	9
89	Hypergastrinemia in animals and man: causes and consequences. Scandinavian Journal of Gastroenterology, 2004, 39, 505-509.	0.6	29
90	Hypergastrinemia induced by partial corpectomy results in ECL-cell carcinoma in male cotton rats. Gastroenterology, 2003, 124, A306.	0.6	1

#	Article	IF	CITATIONS
91	Spontaneous ECL-cell carcinomas in cotton rats are prevented by a somatostatin analogue. Gastroenterology, 2003, 124, A305.	0.6	Ο
92	Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis, 2003, 24, 1887-1896.	1.3	54
93	Skeletal effects of the gastrin receptor antagonist netazepide in H+/K+ATPase beta-subunit deficient mice. Bone Abstracts, 0, , .	0.0	1
94	Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Endocrine Abstracts, 0, , .	0.0	1